ES2751925T5 - Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor - Google Patents

Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor Download PDF

Info

Publication number
ES2751925T5
ES2751925T5 ES15734713T ES15734713T ES2751925T5 ES 2751925 T5 ES2751925 T5 ES 2751925T5 ES 15734713 T ES15734713 T ES 15734713T ES 15734713 T ES15734713 T ES 15734713T ES 2751925 T5 ES2751925 T5 ES 2751925T5
Authority
ES
Spain
Prior art keywords
braf
inhibitor
mutation
nras
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15734713T
Other languages
English (en)
Spanish (es)
Other versions
ES2751925T3 (es
Inventor
Mitchell Paul Levesque
Reinhard Dummer
Daniel Widmer
Marieke Ineke Geertje Raaijmakers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51210291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2751925(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of ES2751925T3 publication Critical patent/ES2751925T3/es
Application granted granted Critical
Publication of ES2751925T5 publication Critical patent/ES2751925T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
ES15734713T 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor Active ES2751925T5 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14176944 2014-07-14
PCT/EP2015/065986 WO2016008853A1 (en) 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor

Publications (2)

Publication Number Publication Date
ES2751925T3 ES2751925T3 (es) 2020-04-02
ES2751925T5 true ES2751925T5 (en) 2025-05-13

Family

ID=51210291

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15734713T Active ES2751925T5 (en) 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor

Country Status (7)

Country Link
US (1) US20190194757A1 (cg-RX-API-DMAC7.html)
EP (1) EP3169797B2 (cg-RX-API-DMAC7.html)
JP (1) JP7036594B2 (cg-RX-API-DMAC7.html)
CN (1) CN107148481A (cg-RX-API-DMAC7.html)
CA (1) CA2953732C (cg-RX-API-DMAC7.html)
ES (1) ES2751925T5 (cg-RX-API-DMAC7.html)
WO (1) WO2016008853A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3063614A1 (en) * 2017-05-16 2018-11-22 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
CN112795647B (zh) * 2019-11-14 2022-08-16 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤标志物及其应用
CN111020033A (zh) * 2019-12-24 2020-04-17 中山大学达安基因股份有限公司 多重检测braf基因突变的试剂盒及方法
US20240288397A1 (en) * 2021-06-23 2024-08-29 Royal Melbourne Institute Of Technology Conductometric sensor for detecting a nucleic acid and a method for the detection thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120252015A1 (en) * 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
US20100285478A1 (en) * 2009-03-27 2010-11-11 Life Technologies Corporation Methods, Compositions, and Kits for Detecting Allelic Variants
EP2632494A4 (en) * 2010-10-28 2016-04-20 Univ Yale Inc METHOD AND COMPOSITIONS FOR THE STUDY AND TREATMENT OF CANCER
JP2014505658A (ja) 2010-11-05 2014-03-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 癌を治療する方法
US20130217721A1 (en) * 2010-11-19 2013-08-22 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
BR112013012485A2 (pt) * 2010-11-19 2016-09-06 Glaxosmithkline Ip No 2 Ltd método de tratamento com inibidor braf
WO2014009319A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
WO2014009318A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
CA2886397A1 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers

Also Published As

Publication number Publication date
ES2751925T3 (es) 2020-04-02
JP2017529094A (ja) 2017-10-05
US20190194757A1 (en) 2019-06-27
WO2016008853A1 (en) 2016-01-21
CN107148481A (zh) 2017-09-08
EP3169797A1 (en) 2017-05-24
CA2953732A1 (en) 2016-01-21
JP7036594B2 (ja) 2022-03-15
EP3169797B1 (en) 2019-08-21
EP3169797B2 (en) 2025-02-19
CA2953732C (en) 2023-09-26

Similar Documents

Publication Publication Date Title
Singh et al. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer
JP7759177B2 (ja) 癌の治療方法
Nalejska et al. Prognostic and predictive biomarkers: tools in personalized oncology
Skaro et al. Prevalence of germline mutations associated with cancer risk in patients with intraductal papillary mucinous neoplasms
US9133523B2 (en) Compositions and methods for detecting cancer metastasis
EP3055429B1 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
ES2751925T5 (en) Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor
US20170082629A1 (en) Diagnostic and prognostic markers for cancer
Liu et al. miR-31-5p-DMD axis as a novel biomarker for predicting the development and prognosis of sporadic early-onset colorectal cancer
WO2014135655A1 (en) Compositions and methods for treating muscle-invasive bladder cancer
US10676792B2 (en) Prognostic and diagnostic methods for colorectal cancer
US20120309640A1 (en) Diagnostic and Prognostic Markers for Cancer
WO2022159852A1 (en) Methods and compositions for treating adenoid cystic carcinoma
Khuong-Quang et al. Recurrent SPECC1L–NTRK fusions in pediatric sarcoma and brain tumors
CN114502745A (zh) 利用脱氧核糖核酸甲基化突变的抗癌免疫治疗反应性预测方法
EP3041956B1 (en) Ddx43 as a biomarker of resistance to mek1/2 inhibitors
ES2792150A1 (es) Metodo para predecir y/o diagnosticar la metastasis del cancer
WO2019213689A1 (en) Determining cancer responsiveness to treatment
US11697845B2 (en) Directing treatments for glioblastoma based on identifying a somatic structural rearrangement upstream from TERT gene
US20240026458A1 (en) Method for Determining Sensitivity to an Antineoplastic Agent
Talaat et al. OPEN ACCESS EDITED BY
Nagelberg et al. Integrative genomics identifies SHPRH as a tumor suppressor gene in lung adenocarcinoma that regulates DNA damage response
Ouyang et al. Long non-coding RNA AFAP1-AS1 promotes alternative splicing of AXIN2 by facilitating SRSFs phase separation to induce drug resistance in lung adenocarcinoma
KR20240026431A (ko) 암의 진단, 전이 가능성 또는 예후 예측용 바이오 마커 및 이의 용도
KR101793174B1 (ko) Golgb1 또는 sf3b3을 이용한 재발암의 진단방법 및 golgb1 또는 sf3b3의 억제제를 함유하는 재발암 치료용 조성물